What is the current United States Insulin Drugs And Delivery Devices Market size?

In 2024, the United States Insulin Drugs And Delivery Devices Market size is expected to reach USD 19.70 billion. Read More

Who are the key players in United States Insulin Drugs And Delivery Devices Market?

Novo Nordisk, Medtronics, Sanofi, Eli Lily and Ypsomped are the major companies operating in the United States Insulin Drugs And Delivery Devices Market. Read More

What years does this United States Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2023?

In 2023, the United States Insulin Drugs And Delivery Devices Market size was estimated at USD 19.17 billion. The report covers the United States Insulin Drugs And Delivery Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the United States Insulin Drugs And Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

United States Insulin Drugs And Delivery Devices Market Share

Q: How big is the United States Insulin Drugs And Delivery Devices Market?

The United States Insulin Drugs And Delivery Devices Market size is expected to reach USD 19.70 billion in 2024 and grow at a CAGR of 2.70% to reach USD 22.5 billion by 2029. Read More

Statistics for the 2023 & 2024 United States Insulin Drugs And Delivery Devices market share, created by Mordor Intelligence™ Industry Reports. United States Insulin Drugs And Delivery Devices share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of United States Insulin Drugs And Delivery Devices Industry

The United States Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Recently, mergers and acquisitions between the players have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.